Effector Therapeutics Inc (EFTR)
eFFECTOR Therapeutics, Inc. is a biotechnology company focused on developing selective translation regulator inhibitors for cancer treatment. Its pipeline includes Zotatifin, an eIF4A inhibitor being studied in a Phase 1/2 trial for solid tumors and previously evaluated in a Phase 2 study in combination with fulvestrant and abemaciclib in ER-positive breast cancer. The company is also developing Tomivosertib, an oral MNK inhibitor in a Phase 2b trial for metastatic non-small cell lung cancer. eFFECTOR Therapeutics also maintains a research collaboration and license agreement with Pfizer Inc. related to small molecules targeting eIF4E. Founded in 2012, the company is headquartered in Solana Beach, California, and its common stock is listed on OTC Markets under the ticker EFTR.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-EFTR
|
—
|
—
|
—
|
—
|
—
|
—
|
Weak
|
—
|
—
|
—
|
0.0%
|
—
|
—
|
—
|
—
|
2.352 K
|
—
|
—
|
—
|
—
|
—
|
—
|